Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics Inc has positioned itself with a robust scientific foundation, underpinned by the promising clinical data from its lead product candidate, PLN-101095, which has shown significant efficacy and tolerability in monotherapy treatment. The company's proprietary integrin-targeted delivery platform presents additional potential for unlocking value across various disease areas, further bolstered by an accelerated development plan that includes initiation of a Phase 1b trial. Additionally, the experienced management team minimizes risk associated with execution and regulatory interactions, instilling confidence in Pliant's competitive standing in a growing market for integrin-based therapies.

Bears say

Pliant Therapeutics Inc faces significant risks associated with the clinical development of its lead product candidate, PLN-101095, particularly given the historical challenges related to integrin inhibitors. The potential for clinical setbacks can lead to delays or outright failures in drug development, raising concerns about the viability of its pipeline. Additionally, the company's recent decrease in market capitalization can be attributed to an updated cash position and increased share counts, further highlighting financial instability and investor uncertainty.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Apr 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.